Open AccessNivolumab: 5 years from the day of international registration of immunotherapy of metastatic kidney cancer
Author(s) -
И. В. Тимофеев
Publication year - 2021
Publication title -
zlokačestvennye opuholi
Language(s) - English
Resource type - Journals
eISSN - 2587-6813
pISSN - 2224-5057
DOI - 10.18027/2224-5057-2020-10-4-21-29
Subject(s) - nivolumab , medicine , immunotherapy , food and drug administration , renal cell carcinoma , metastatic melanoma , oncology , kidney cancer , cancer immunotherapy , cancer , pharmacology
Five years ago, on November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma, thus ushering in a new era of immunotherapy for this tumor. The purpose of this review is to systematize the accumulated results of studies of nivolumab in monotherapy and in combinations.